Effect of lurasidone plus sulpiride on treatment efficacy, psychiatric manifestations, and quality of life among patients with schizophrenia

Table 1 General characteristics of patients in the two groups

Indicators	Control group (n = 50)	Observation group (n = 60)	χ²/t	P value
Sex (male/female)	30/20	31/29	0.767	0.876
Age (years)	54.46 ± 7.22	52.20 ± 8.61	1.474	0.144
Disease course (years)	6.26 ± 2.00	6.05 ± 2.60	0.467	0.641
Body mass index (kg/m2)	25.12 ± 2.18	24.45 ± 2.20	1.597	0.113
Years of education (years)	10.80 ± 2.73	10.00 ± 3.15	1.408	0.162
Concomitant medications (yes/no)	12/38	10/50	0.917	0.338
Tobacco use (yes/no)	18/32	15/45	1.571	0.210
Regular exercise habits (yes/no)	10/40	8/52	0.886	0.347

Concomitant medications: Benzodiazepines, anticholinergics, etc.; tobacco use defined as ≥ 1 cigarette per day; regular exercise habits: ≥ 3 sessions per week, each lasting ≥ 30 minutes.